Invivyd receives FDA IND clearance for VYD222 to prevent Covid-19

26 Apr 2023
www.pharmaceutical-technology.com
Phase 1INDVaccineGene TherapyImmunotherapy
Invivyd receives FDA IND clearance for VYD222 to prevent Covid-19
Preview
Source: Pharmaceutical Technology
VYD222 is being developed to prevent Covid-19 in vulnerable people, including immunocompromised individuals. Credit: Fusion Medical Animation on Unsplash.
Invivyd has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application for VYD222 to prevent Covid-19.
VYD222 is a new monoclonal antibody (mAb) candidate and is being developed to prevent Covid-19 in vulnerable people, including immunocompromised individuals.
Recommended Reports
Invivyd receives FDA IND clearance for VYD222 to prevent Covid-19
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Rnai Gene Therapy To Inhibit Stmn1 For Solid Tumor in Solid Tumor GlobalData
Invivyd receives FDA IND clearance for VYD222 to prevent Covid-19
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Mezagitamab in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic ... GlobalData
View all
Engineered from adintrevimab (ADG20), the antibody showed in vitro neutralising activity against dominant variants of concern, including XBB.1.5.
It is being assessed in an ongoing Phase I healthy volunteer clinical trial in Australia.
The company commenced dosing participants in March 2023.
Invivyd chief medical officer Pete Schmidt said: “For the millions of immunocompromised people around the world who may not generate adequate protection from SARS-CoV-2 vaccines, there is an urgent need for new therapeutics that provide the rapid, passive immunity that results from the direct delivery of mAbs.
“With the previously authorised anti-SARS-CoV-2 mAbs losing activity against current variants of concern, we look forward to continuing to work with the FDA and global regulators to advance VYD222 and our platform-based approach to development.”
The dose-ranging, blinded, placebo-controlled, randomised Phase I trial has been designed for assessing the pharmacokinetics, tolerability, safety and serum virus-neutralising activity of VYD222 in healthy adult volunteers.
The trial will assess three different doses of VYD222, each administered as a single IV infusion.
The company stated that all dose levels will provide durability in the face of viral evolution and flexibility during the regulatory submission.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.